Detalhe da pesquisa
1.
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Invest New Drugs
; 35(5): 599-607, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28144789